Gynecologic Cancers

Latest News

FDA Approves Onbody Administration System for Pegfigrastim Biosimilar
FDA Approves Onbody Administration System for Pegfigrastim Biosimilar

January 6th 2024

The Food and Drug Administration approved an on-body delivery system for pegfilgrastim-cbqv, a biosimilar of pegfilgrastim.

gynecologic cancer
Antibody-Drug Conjugates Offer Platinum-Resistant Patients New Options in Gynecologic Cancers

December 19th 2023

FDA
The FDA is Considering Granting Regular Approval to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer

December 13th 2023

Cervical Cancer
Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial

December 3rd 2023

gynecologic cancer
Why a Trauma-Informed Approach Is Ideal in Gynecologic Cancer Care

November 29th 2023

Latest CME Events & Activities

Miami Breast 2024: Affiliated CE Symposia

March 7, 2024 - March 10, 2024

View More

The Latest on Acute Lymphocytic Leukemia

View More

A Focus on Acute Myeloid Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.